Print Page

Products found to contain undeclared medicines

The United States: Public Notification: JaDera PLUS contains hidden drug ingredients sibutramine, N-desmethylsibutramine and benproperine
The US Food and Drug Administration (FDA) is advising consumers not to purchase or use JaDera PLUS, a product promoted for weight loss. This product was identified during an examination of international mail shipments. FDA laboratory analysis confirmed that JaDera PLUS contains sibutramine, N-desmethylsibutramine, and benproperine.

Sibutramine is a controlled substance that was removed from the market in Oct 2010 for safety reasons. N-desmethylsibutramine is a substance structurally similar to sibutramine. Sibutramine poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or heart rate in some people and may present a significant risk for people with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking. Benproperine is an active ingredient not approved by FDA, and therefore its safety and efficacy have not been established.

Please refer to the following website in FDA for details:

In Hong Kong, the above product is not a registered pharmaceutical product.

Ends/Wednesday, Sep 11, 2019
Issued at HKT 15:00